Lexicon Pharmaceuticals (NASDAQ:LXRX) Price Target Raised to $6.00

Lexicon Pharmaceuticals (NASDAQ:LXRX) had its price target increased by HC Wainwright from $4.00 to $6.00 in a research report report published on Thursday morning, MarketBeat reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ FY2027 earnings at ($0.21) EPS and FY2028 earnings at ($0.18) EPS.

A number of other research analysts also recently weighed in on LXRX. Wall Street Zen downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $3.95.

Lexicon Pharmaceuticals Trading Up 4.3%

LXRX opened at $1.71 on Thursday. The firm has a 50 day simple moving average of $1.36 and a 200 day simple moving average of $1.33. Lexicon Pharmaceuticals has a fifty-two week low of $0.32 and a fifty-two week high of $1.83. The company has a market cap of $621.53 million, a price-to-earnings ratio of -12.21 and a beta of 0.94. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.64 and a quick ratio of 5.63.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Thursday, March 5th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 101.08% and a negative return on equity of 40.53%. The firm had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $3.14 million. On average, sell-side analysts anticipate that Lexicon Pharmaceuticals will post -0.66 earnings per share for the current year.

Insider Activity at Lexicon Pharmaceuticals

In other news, Director Invus Global Management, Llc purchased 1,538,462 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, February 2nd. The shares were bought at an average cost of $1.30 per share, with a total value of $2,000,000.60. Following the completion of the transaction, the director directly owned 1,538,462 shares in the company, valued at $2,000,000.60. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Raymond Debbane purchased 100,000 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was purchased at an average cost of $1.47 per share, with a total value of $147,000.00. Following the acquisition, the director directly owned 1,904,186 shares in the company, valued at $2,799,153.42. This trade represents a 5.54% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 1,790,462 shares of company stock valued at $2,369,981 in the last ninety days. Insiders own 13.90% of the company’s stock.

Institutional Trading of Lexicon Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in LXRX. Security National Bank of Sioux City Iowa IA bought a new position in Lexicon Pharmaceuticals during the fourth quarter worth about $31,000. Hudson Bay Capital Management LP acquired a new position in Lexicon Pharmaceuticals in the second quarter valued at about $26,000. Leonteq Securities AG bought a new stake in shares of Lexicon Pharmaceuticals in the fourth quarter worth about $34,000. Vermillion & White Wealth Management Group LLC raised its position in shares of Lexicon Pharmaceuticals by 400.0% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 26,000 shares during the period. Finally, EntryPoint Capital LLC acquired a new stake in shares of Lexicon Pharmaceuticals during the fourth quarter worth about $39,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Key Stories Impacting Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: Q4 results beat expectations — GAAP EPS of -$0.04 vs. -$0.07 consensus and revenue of $5.49M vs. $3.14M expected, which relieved near-term execution concerns and likely helped the stock. Earnings beat summary
• Positive Sentiment: Clinical progress: management confirmed sotagliflozin pivotal milestones are on schedule (including planned NDA resubmission in T1D and enrollment of the SONATA HCM study) and reported a positive End‑of‑Phase‑2 meeting with the FDA for pilavapadin, supporting Phase 3 readiness. These program updates materially de‑risk future value drivers. Press release with clinical updates
• Positive Sentiment: Balance-sheet boost — management disclosed more than $100M in additional cash from a capital raise plus a Novo Nordisk milestone payment, improving runway and reducing near‑term financing risk. Press release with financing detail
• Positive Sentiment: Analyst upgrade / price-target raise — H.C. Wainwright reiterated a Buy rating and raised its target to $6, signaling bullish analyst conviction and providing a large implied upside that can attract momentum buyers. Analyst note / PT raise
• Neutral Sentiment: Management hosted an earnings call and published slides/transcript; these provide more detail for investors but are informational rather than catalytic. Earnings call transcript
• Negative Sentiment: Company remains unprofitable with a negative net margin (~96.8%) and negative return on equity; consensus still forecast a full‑year loss (current consensus ~ -$0.66 EPS), so fundamentals remain challenged absent clinical or commercial validation. Earnings / metrics summary
• Negative Sentiment: Biotech execution and regulatory risk persist — upcoming clinical readouts and the NDA resubmission are binary events that could reverse gains if outcomes disappoint. Clinical & regulatory update

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.